OSR Holdings Targets China's Massive Diabetes Market Through Sinopharm Partnership

New York, Thursday, 19 March 2026.
OSR Holdings is targeting China’s $12 billion diabetes market, signing an agreement with Sinopharm to explore commercializing its needle-free glucose monitoring technology for over 140 million patients.